The combined company’s shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively on August 16, 2024 The combined company’s shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively on August 16, 2024

Originally posted here:
Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

Approval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers

Here is the original post:
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns

Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board

See more here:
Codexis Publishes FY2023 Sustainability Disclosures

Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages

See the rest here:
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. Phoenix is the pharmaceutical industry's gold standard in pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software. The Phoenix Platform is used by more than 75 of the top 100 pharmaceutical companies worldwide. Eleven regulatory agencies, including the U.S. FDA, Japan PMDA, and China NMPA, rely on Phoenix to evaluate life-saving drug candidates. Version 8.5 is the latest release from Certara’s Phoenix Platform, available as a hosted solution for maximum performance and lower total cost of ownership.

Read more:
Certara Launches Phoenix™ Version 8.5 Drug Development Software

REYKJAVIK, Iceland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2024 and provided a summary of recent corporate highlights.

Go here to read the rest:
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that its special meeting of shareholders (the "Meeting") convened on August 15, 2024, at 1:00 p.m. (ET) has been adjourned to September 5, 2024 at 1 p.m. (ET), without business being considered, due to a lack of quorum.

See original here:
Aptose Announces Adjournment of its Special Meeting of Shareholders

COPENHAGEN, Denmark, August 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) has submitted clinical data to the European Medicines Agency (EMA) to support the extension of the IMVANEX® (MVA-BN®) smallpox and mpox vaccine indication to include adolescents 12 to 17 years of age.

Follow this link:
Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Oslo, Norway, 16 August 2024

Read the original:
Vistin Pharma ASA: Invitation to Q2 2024 conference call

NEW YORK and MAINZ, Germany, August 16, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The combination candidate consists of Pfizer’s mRNA-based influenza vaccine candidate with the companies’ licensed COVID-19 vaccine. The Phase 3 trial measured two primary immunogenicity objectives (immunogenicity against SARS-CoV-2 as well as immunogenicity against influenza A and B), of which one was met. In a separate Phase 2 trial, Pfizer evaluated trivalent (“tIRV”) influenza mRNA standalone vaccine candidates which demonstrated robust immunogenicity in individuals 18-64 years of age. The companies are evaluating adjustments to the combination vaccine candidate aimed at improving immune responses against influenza B and will discuss next steps with health authorities.

Read the rest here:
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

World Health Organization (WHO) has declared spread of mpox in multiple African countries a public health emergency of international concern (PHEIC) 1

Read more:
Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares...

– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications

See the original post here:
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update

MONTREAL, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Quebec spanning over 1,650,000 sq. ft., today announced that the Company has achieved its highest national market share of 3.2% in July 2024 which places Cannara as the 9th largest licensed producer in Canada by market share1.

See the original post:
Cannara Biotech Achieves its Highest National Market Share of 3.2% in July 2024 and Announces Investor Webcast Scheduled for August 20, 2024

Media Release

Follow this link:
Genmab Announces Changes to its Executive Committee

Hamilton, Bermuda, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Altamira Medica Ltd. (“Altamira” or the “Company”), an associate company of Altamira Therapeutics Ltd. (Nasdaq:CYTO), today announced that its preservative-free, drug-free Bentrio® nasal spray for allergic rhinitis was tested successfully for the absence of more than 230 prohibited substances listed by the World Anti-Doping Agency (WADA). This finding further confirms Bentrio’s suitability for athletes who must comply with antidoping regulations but at the same time need to protect themselves against airborne allergens or other particles.

Read the original:
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances

Company announcement – No. 40 / 2024

The rest is here:
Zealand Pharma major shareholder announcement: Bank of America Corporation

ROCKVILLE, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every twenty five (25) shares of common stock, effective as of 12:01 a.m. (Eastern Time) on August 26, 2024 (the “Effective Date”). The Company’s common stock will begin trading on a split-adjusted basis when the market opens on August 26, 2024. The reverse stock split was authorized by the Company’s Board of Directors on August 15, 2024. Pursuant to the laws of the State of Nevada, the Company’s state of incorporation, the Company’s Board of Directors has the authority to effect a reverse stock split without shareholder approval if the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced. The Company will file a certificate of change to its articles of incorporation, as amended, with the Secretary of State of Nevada to effect the reverse stock split. The Company’s common stock will continue to trade on the NYSE American under the stock ticker “TOVX” but will trade under the new CUSIP number 87164U 508.

Read more:
Theriva Biologics Announces Reverse Stock Split

Vancouver, Canada, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the international Patent Cooperation Treaty (“PCT”) as part of the company’s ongoing collaboration with the with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”) pursuant to the exclusive licensing agreement that the Company entered into with Yissum.

View post:
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental...

Special dividend estimated to be $1.59 per share

Originally posted here:
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

SciSparc will receive consideration in shares, and in addition may receive cash payments and fees if certain development milestones are met

See original here:
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million